Related Experiment Videos
Aminophylline therapy for idiopathic apnea in premature infants: effects on lung function
Insights
Aminophylline significantly reduced apnea episodes in premature infants. However, it did not improve their lung function or oxygenation, suggesting a central nervous system effect is responsible for its effectiveness.
Area of Science:
- Neonatology
- Pediatric Pulmonology
- Pharmacology
Background:
- Premature infants often experience apnea, a significant concern in neonatal care.
- Compromised pulmonary function is common in premature infants, impacting respiratory stability.
- Alveolar-arterial PO2 gradient, lung compliance, and inspiratory resistance are key indicators of lung function.
Purpose of the Study:
- To investigate the effect of aminophylline on lung function in premature infants with apnea.
- To determine if aminophylline improves pulmonary function parameters in this vulnerable population.
- To elucidate the mechanism by which aminophylline exerts its therapeutic effect on apnea.
Main Methods:
- A cohort of 14 premature infants with apnea was studied.
- Pulmonary function was assessed, including alveolar-arterial PO2 gradient, lung compliance, and inspiratory resistance.
- The impact of aminophylline therapy on these parameters and the incidence of apneic episodes was measured.
Main Results:
- Aminophylline therapy did not significantly alter lung function parameters.
- A notable decrease in the incidence of apneic episodes was observed (from 29.7 to 4.4 per day).
- The alveolar-arterial PO2 gradient remained large, and lung compliance was low normal.
Conclusions:
- Aminophylline's effectiveness in treating apnea in premature infants is likely due to its central stimulant properties.
- The therapeutic benefit is not mediated by improvements in lung function or oxygenation.
- Further research into the central mechanisms of aminophylline in neonatal apnea is warranted.
Abstract:
The effect of aminophylline on lung function was studied in 14 premature infants with apnea (gestational age, 30.2 weeks; birth weight, 1.052 gm). The infants showed compromised pulmonary function with a large difference in alveolar-arterial PO2 gradient (83.9 mm Hg), a low normal lung compliance of 1.1 ml/cm H2O . kg, and a normal inspiratory resistance of 45.3 cm H2O/liter/sec. Aminophylline therapy did not change these functions significantly, but it decreased the incidence of apneic episodes from 29.7 to 4.4 per day. The effectiveness of aminophylline in treating apnea in premature infants must be related to its central stimulating effect and not to an improvement in lung function and oxygenation.